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See Article, pages 486–493There is exponential interest in non-alcoholic fatty liver disease
(NAFLD) as a cause of chronic liver disease in the last decade
[1]. The epidemic of obesity due to changes in life style and nutri-
tional habits in Western countries has greatly contributed to the
rapid increase in prevalence of NAFLD. In addition to obesity,
NAFLD is strongly associated with diabetes mellitus and insulin
resistance that are believed to be a consequence of low physical
activity and increased fat mass as well as the metabolic syndrome
[2,3].
The ﬁrst observation that a reduction in muscle tissue (better
known as sarcopenia) could be involved in NAFLD came from the
Korean Sarcopenic Obesity Study [4]. The authors found that indi-
viduals with age-related sarcopenia which was associated with
higher body mass index (BMI) and fat mass had an increased
prevalence of NAFLD. By analyzing the same database, previous
studies had shown that, during aging, the increase in fat mass
and the decrease in muscle mass resulted in an increase in meta-
bolic disorders [5]. Type 2 diabetes has also been found to be
independently associated with sarcopenia [6]. These studies have
led to the hypothesis that leptin and other adipocytokines from
the adipose tissue increase muscle catabolism and consequent
sarcopenia and reduced physical activity which, through a vicious
cycle, results in increased fat accumulation and weight gain.
In this issue of Journal of Hepatology, Lee and coworkers [7]
provide further information on the relationship between sarcope-
nia and NAFLD by analyzing the data from the Korea National
Health and Nutrition Examination Survey.
The opportunity to derive data from this large population
study was based on the application of non-invasive scores, with
an acceptable positive predictive index, for the diagnosis of
NAFLD. Dual-energy X-ray absorptiometry was used for the
assessment of body composition to deﬁne changes in muscle
mass. Sarcopenia was diagnosed using the skeletal muscle index
(SMI) and deﬁned as <1 standard deviation below the average of a
young reference population.Journal of Hepatology 20
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between sarcopenia and NAFLD regardless of obesity or meta-
bolic syndrome. Both non-obese and obese subjects showed a sig-
niﬁcantly increased prevalence of NAFLD when sarcopenia was
present (non-obese non–sarcopenic: 4–14% vs. non–obese sar-
copenic: 9–30%; p <0.001, and obese non–sarcopenic 50–72% vs.
obese sarcopenic 61–83%; p <0.001). Similar results were found
when patients were stratiﬁed by the presence or absence of
metabolic syndrome. Interestingly, the authors also examined
the impact of regular exercise in patients with NAFLD and found
that in obese subjects with preserved skeletal muscle mass, reg-
ular exercise was associated with a reduced probability of NAFLD
(46 vs. 55% p <0.001). Furthermore, among patients with NAFLD,
the presence of sarcopenia was also independently associated
with a higher probability of advanced liver ﬁbrosis (evaluated
through ﬁbrosis predictors).
It is important to note that in the study by Lee, diagnosis of
sarcopenia was made using the SMI, a ratio of the appendicular
skeletal muscle (ASM) and body weight (BW). SMI may decrease
when the fat mass is enhanced, either for obesity or for aging, due
to the increase in body mass and therefore the absolute decrease
in muscle tissue may be lower than indicated [8]. Recently how-
ever, in a more limited group of patients, sarcopenia evaluated
using computed tomographic (CT) scans, a method which allows
precise quantiﬁcation of muscle mass, was also reported to be
associated to the development of NASH or NASH and cirrhosis
[9,10].
An increasingly recognized limitation of body composition
measurements is the difﬁculty of quantifying muscle mass with
precision [11,12]. A number of methods have been described
including DEXA and image analysis using CT or magnetic reso-
nance imaging (MRI). A major limitation of CT and MRI despite
their recognized accuracy in identifying skeletal muscle is due
to their cost and logistics in population studies. DEXA remains
the best option and even though DEXA measures non-fat mass
and not muscle mass directly, appendicular non-fat, non-bone
mass is predominantly skeletal muscle. Furthermore, the authors
acknowledge that muscle mass can be measured using DEXA but
the impact on quality of the muscle is not known. This is
especially relevant since in type 2 diabetes mellitus, an insulin
resistant state, inter- and intra-myocellular fat are increased.15 vol. 63 j 309–311
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Fig. 1. Skeletal muscle centric approach to non-alcoholic fatty liver disease
(NAFLD). Myokines, speciﬁcally myostatin, cross-talk with adipocytokine,
adiponectin contributes to the development and progression of NAFLD.
EditorialNeither muscle function or strength were measured in the study
by Lee [7] and it is not clear if the sarcopenia in patients with
NAFLD and metabolic syndrome is associated with reduced mus-
cle strength. Contractile function of the muscle does correlate
with outcomes in chronic diseases but whether such an associa-
tion exists in metabolic dysfunction is not known at this time.
To understand if the association between sarcopenia and
NAFLD is a cause or a consequence, there is a need to identify
the possible pathophysiological mechanism relating muscle, adi-
pose tissue and the liver. Recognition that the skeletal muscle is
an endocrine organ secreting various myokines may help to
understand its role in the development of fatty liver [13] (Fig. 1).
Focusing on the skeletal muscle and on the mediators that link
the muscle-liver-adipose tissue axis, is likely to provide a very
novel and exciting area for therapeutic development [14,15]. A
number of animal studies have shown that myostatin, a TGFb
superfamily member, which was initially discovered as a regula-
tor of skeletal muscle mass, has signiﬁcant hepatic effects by reg-
ulating skeletal muscle metabolism. Blocking myostatin not only
increases muscle mass but also protects mice from fatty liver and
improves insulin resistance [16,17]. Furthermore, myostatin also
promotes an increase in muscle mass depending on the time of
exposure of adipocytes in their development [18]. Myostatin
receptor, Activin IIbr, has been reported, albeit in abstract form
only, in hepatic stellate cells. This raises the interesting question
of whether fatty liver results in sarcopenia via activation of myo-
statin in the skeletal muscle, or whether is sarcopenia the pri-
mary abnormality mediated by myostatin that functions in an
endocrine manner to activate the ﬁbrogenic hepatic stellate cells.
Adiponectin is another potential mediator of the adipose tissue
muscle axis that alters hepatic metabolism. Adiponectin recep-
tors in the muscle have been reported to regulate insulin signal-
ing and increase fatty acid oxidation but whether there is an
adiponectin-myostatin cross-talk has been speculated upon but
never proven [15]. Obesity and adipose tissue inﬂammation are
accompanied by hypo-adiponectinemia and adiponectin
improves insulin signaling. Since myostatin increases adipose tis-
sue mass, and this in turn decreases adiponectin secretion, the
liver-muscle-adipose tissue perturbation may actually begin in
the skeletal muscle and act on both the liver and adipose tissue.
Interleukin-6 is another myokine that potentially regulates310 Journal of Hepatology 201hepatic fatty acid oxidation via an AMPK dependent mechanism.
Secretory and signaling perturbations of other myokines that reg-
ulate lipid and glucose metabolism that include myonectin and
irisin have been suggested to contribute to the development of
insulin resistance and fatty liver [19,20]. In addition to myokines
regulating metabolism, skeletal muscle contributes to the resting
energy and maximum energy expenditure [21]. Skeletal muscle
mitochondrial dysfunction has been reported with muscle atro-
phy and whether impaired skeletal muscle substrate and energy
utilization contribute to the development and progression of
fatty liver is not known. Given the beneﬁcial effects of increased
physical activity on both the hepatic and non-hepatic compo-
nents of the metabolic syndrome, targeting skeletal muscle mito-
chondrial function is another attractive approach to treat
metabolic disorders including NAFLD.
The present study adds to the existing literature on sarcopenia
and its impact on severity and possibly outcomes in NAFLD.
These are exciting translational human data generated from basic
biology of the muscle-liver axis that provide a compelling ratio-
nale to study the skeletal muscle as a primary therapeutic target
in NAFLD and metabolic syndrome. Although the study of Lee and
coworkers has limitations, including the absence of histological
diagnosis of NAFLD and the use of muscular indices, identifying
a strong and direct contribution of the skeletal muscle to hepatic
disease is likely to result in a broader therapeutic approach to
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